Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

FARA Joins Nasdaq’s Live Broadcast on #GivingTuesday

FARA, Adverum Biotechnologies, Catabasis Pharmaceuticals and Horizon Pharma plc
Join Nasdaq’s Live Broadcast on #GivingTuesday

New York- November 29- The Friedreich’s Ataxia Research Alliance (FARA), Adverum Biotechnologies, Catabasis Pharmaceuticals (Nasdaq:CATB), and Horizon Pharma plc mark #GivingTuesday on November 29 by teaming up for a live informational Facebook broadcast from Nasdaq MarketSite Entering its fifth year, #GivingTuesday is a global day of giving fueled by the power of social media and collaboration.

FARA’s Executive Director, Jennifer Farmer, will moderate a panel, including select Nasdaq-listed companies with product candidates focused on Friedreich’s ataxia, to raise awareness of this rare disease and the ongoing work to develop treatments. The panel will discuss different approaches to treatment development for FA including small molecules, biologics and gene therapy, and how these can be synergistic. They will also highlight ways in which advocacy organizations and pharmaceutical organizations have partnered to expedite research.  The panel will include:

  • Amber Salzman, PhD- President & CEO at Adverum Biotechnologies, Inc. 
  • Andrew Nichols, PhD- Chief Scientific Officer at Catabasis
  • Jeffrey Sherman, M.D., FACP-Executive Vice President, Research and Development and Chief Medical Officer at Horizon Pharma plc. 

Read the full press release HERE.

Farmer states, “GivingTuesday has inspired countless collaborative endeavors in the name of giving back. We are grateful to Nasdaq for the opportunity to share some of the ongoing collaborative efforts in the rare disease space. At FARA, we believe we are strongest and most efficient when all of our stakeholders work together- patients, donors, scientists and pharmaceutical companies.”

To view the live broadcast visit Nasdaq’s Facebook page on November 29 from 12:30pm-1pm: https://www.facebook.com/NASDAQ/. The recorded broadcast will be available shortly following on the same site. To donate on #GivingTuesday, visit cureFA.org.

About FA
Friedreich’s ataxia is a rare, degenerative, life-shortening neuro-muscular disorder that affects children and adults, and involves the loss of strength and coordination usually leading to wheelchair use; diminished vision, hearing and speech; scoliosis (curvature of the spine); increased risk of diabetes; and a life-threatening heart condition. There are no FDA-approved treatments.

About FARA
The Friedreich's Ataxia Research Alliance (FARA) is a 501(c)(3), non-profit, charitable organization dedicated to accelerating research leading to treatments and a cure for Friedreich's ataxia. www.CureFA.org

About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet AMD, A1AT deficiency, and hereditary angioedema. Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum has clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information please visit www.adverum.com.

About Catabasis Pharmaceuticals
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.

About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers the company's LinkedIn page.

SHARE

FacebookTwitterLinkedinShare on Google+
Event I.jpg

News & Press Archives